Oct 2026
Clinical impact of prospective circulating tumour DNA testing for minimal residual disease in colorectal cancer: the INTERCEPT programme experience.
BACKGROUND The impact of circulating tumour DNA (ctDNA) detection, which informs minimal residual disease (MRD) after curative treatment, remains debated especially for stage IV patients. OBJECTIVE The study objectives were to evaluate the prognostic role of MRD and to estimate lead time (LT) at different timepoints...
G. Maddalena, K. Aziz, Ryan Sun et al.
· Gut · 0 citations